Bismuth Subsalicylate
drugOn this page
Also known as Bismuth salicylateBismukoteCorrective suspensionGastro-coteNSC-759117Pepto-bismolSID29218057SID144205951SID225144280
Summary
Bismuth Subsalicylate (CHEMBL1120) is an approved small molecule; indicated across 5 conditions including diarrheal disease and helicobacter pylori infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 5 conditions
- Clinical trials: 9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1120 |
| Name | Bismuth Subsalicylate |
| Type | Small molecule |
| Max phase | 4 |
Also known as: Bismuth salicylate, Bismuth subsalicylate, Bismukote, Corrective suspension, Gastro-cote, NSC-759117, Pepto-bismol, SID29218057, Bismuth Subsalicylate, BISMUTH SUBSALICYLATE, SID144205951, SID225144280
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| LMNA | 7.3 | Potency | 50.1 | nM | CHEMBL_ACT_3647945 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diarrheal disease | 4 | MONDO:0001673 | HP:0002014 |
| Helicobacter pylori infectious disease | 3 | MONDO:0006781 | EFO:1000961 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 4 |
| PHASE3 | 2 |
| PHASE2 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01742429 | PHASE4 | COMPLETED | Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection |
| NCT03592082 | PHASE4 | WITHDRAWN | Use of Bismuth Subsalicylate in Clostridium Difficile Colitis |
| NCT03757650 | PHASE4 | COMPLETED | THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY |
| NCT04811339 | PHASE4 | COMPLETED | Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol) |
| NCT01481844 | PHASE3 | COMPLETED | Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection |
| NCT03535272 | PHASE3 | TERMINATED | Bismuth Subsalicylate’s Role in the Prevention of Travelers’ Diarrhea |
| NCT00002682 | PHASE2 | COMPLETED | Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach |
| NCT05930197 | PHASE1 | COMPLETED | Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults |
| NCT02047162 | Not specified | COMPLETED | Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients–Pakistan |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).